Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322239 · ClinicalTrials.gov registry record · NA
Resting State Changes Following Theta Burst Stimulation
A NA study of Brain Connectivity, sponsored by Nicholas Balderston, PhD.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05322239: Recruiting NA study of Brain Connectivity, sponsored by Nicholas Balderston, PhD.
NCT05322239 is a NA study of Brain Connectivity that is actively recruiting participants, run by Nicholas Balderston, PhD. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05322239, a NA study of Brain Connectivity, is actively recruiting participants, sponsored by Nicholas Balderston, PhD.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Transcranial magnetic stimulation (TMS) is increasingly being applied to effectively treat mental illness, however efforts to quantify the effects of TMS on the network architecture of the brain have largely been limited in scope and tied to specific neurologic and psychiatric disorders. The objective of the current work is to build and validate a whole-brain, domain-general model of brain connectivity changes following TMS, based on physical models of the current distribution at the cortex. PUBLIC HEALTH RELEVANCE: This work is relevant to public health because it will provide direct evidence that brain connectivity changes following neuromodulatory TMS vary as a function of the current density at the cortex, which can be used to predict psychiatric symptom change following neuromodulatory TMS.
Primary Outcome
Investigators will measure resting state functional connectivity 24 hours after first dose of continuous or intermittent theta burst stimulation.
Conditions Studied
Interventions
- DEVICE Intermittent Theta Burst Stimulation
- DEVICE Continuous Theta Burst Stimulation
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2027-08-01 |
| Phase | NA |
What NCT05322239 shows while recruiting
NCT05322239 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Brain Connectivity appearing as the primary indexed condition, and to 2 interventions - of which Intermittent Theta Burst Stimulation is the first listed.
NCT05322239 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05322239 about?
NCT05322239 is a clinical study titled "Resting State Changes Following Theta Burst Stimulation". Transcranial magnetic stimulation (TMS) is increasingly being applied to effectively treat mental illness, however efforts to quantify the effects of TMS on the network architecture of the brain have largely been limited in scope and tied to specific neurologic and psychiatric disorders. The objecti...
What is the current status of trial NCT05322239?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2022-11-17. Estimated completion is 2027-08-01.
What conditions does trial NCT05322239 study?
This clinical trial studies the following conditions: Brain Connectivity.
What interventions are being tested in trial NCT05322239?
The interventions under investigation include: Intermittent Theta Burst Stimulation (DEVICE), Continuous Theta Burst Stimulation (DEVICE).
Who is sponsoring clinical trial NCT05322239?
This trial is sponsored by Nicholas Balderston, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05322239 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05322239's enrollment target sits among peer trials
200 506th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI